AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 37550123 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravascular imaging-guided PCI (IVUS or OCT)
Number of subjects: 1507
Study 37550123 — intervention group
Group type: COMPARATOR
Intervention: Angiography-guided PCI
Number of subjects: 1507
Study 37550129 — intervention group
Group type: EXPERIMENTAL
Intervention: Breastfeeding Problems Management Model (BPMM)
Number of subjects: 50
Study 37550129 — intervention group
Group type: COMPARATOR
Intervention: Routine care (Control)
Number of subjects: 50
Study 37550157 — intervention group
Group type: EXPERIMENTAL
Intervention: Elevated serum alkaline phosphatase (ALP) quartile Q4 (ALP >83.00 U/L)
Number of subjects: 22989
Study 37550314 — intervention group
Group type: EXPERIMENTAL
Intervention: Ulotaront
Number of subjects: 0
Study 37550429 — intervention group
Group type: EXPERIMENTAL
Intervention: Blinatumomab (immunotherapy drug)
Number of subjects: 0
Study 37550634 — intervention group
Group type: EXPERIMENTAL
Intervention: Neoadjuvant mFOLFIRINOX followed by surgery and adjuvant mFOLFIRINOX (8 cycles neoadjuvant and 4 cycles adjuvant)
Number of subjects: 378
Study 37550634 — intervention group
Group type: COMPARATOR
Intervention: Adjuvant mFOLFIRINOX (only)
Number of subjects: 378
Study 37550656 — intervention group
Group type: EXPERIMENTAL
Intervention: General practitioner health care utilization (HCU)
Number of subjects: 17822
Study 37550656 — intervention group
Group type: EXPERIMENTAL
Intervention: Psychologist/Psychiatrist health care utilization (HCU)
Number of subjects: 17822
Study 37550656 — intervention group
Group type: EXPERIMENTAL
Intervention: Psychiatric hospital services health care utilization (HCU)
Number of subjects: 17822
Study 37550656 — intervention group
Group type: EXPERIMENTAL
Intervention: Prognostic models for long-term psychologist/psychiatrist and psychiatric hospital HCU
Number of subjects: 17822
Study 37550656 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall health care utilization trends
Number of subjects: 17822
Study 37550693 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients with stress-related disorders (adjustment disorder and exhaustion disorder)
Number of subjects: 266
Study 37550693 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients with exhaustion disorder
Number of subjects: 266
Study 37550693 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-reported memory impairment
Number of subjects: 266
Study 37550693 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-reported burnout symptoms
Number of subjects: 266
Study 37550693 — intervention group
Group type: COMPARATOR
Intervention: Healthy normative group
Number of subjects: 266
Study 37550703 — intervention group
Group type: EXPERIMENTAL
Intervention: Remote ischemic conditioning
Number of subjects: 44
Study 37550703 — intervention group
Group type: COMPARATOR
Intervention: Placebo remote ischemic conditioning
Number of subjects: 44
Study 37550711 — intervention group
Group type: EXPERIMENTAL
Intervention: Proximal Row Carpectomy (PRC)
Number of subjects: 0
Study 37550711 — intervention group
Group type: COMPARATOR
Intervention: Four-Corner Arthrodesis (FCA)
Number of subjects: 0
Study 37550727 — intervention group
Group type: EXPERIMENTAL
Intervention: Bony decompression with duroplasty
Number of subjects: 222
Study 37550727 — intervention group
Group type: COMPARATOR
Intervention: Bony decompression alone
Number of subjects: 222
Study 37550730 — intervention group
Group type: EXPERIMENTAL
Intervention: Adapted TranS-C
Number of subjects: 130
Study 37550730 — intervention group
Group type: EXPERIMENTAL
Intervention: Standard TranS-C
Number of subjects: 130
Study 37550730 — intervention group
Group type: COMPARATOR
Intervention: Usual care followed by delayed treatment with TranS-C (UC-DT)
Number of subjects: 130
Study 37550740 — intervention group
Group type: EXPERIMENTAL
Intervention: Theoretical training plus simulation-based training (4 centers)
Number of subjects: 8
Study 37550740 — intervention group
Group type: COMPARATOR
Intervention: Theoretical training alone (4 centers)
Number of subjects: 8
Study 37550831 — intervention group
Group type: EXPERIMENTAL
Intervention: Caregiver contribution to self-care maintenance
Number of subjects: 510
Study 37550831 — intervention group
Group type: EXPERIMENTAL
Intervention: Patient self-care maintenance
Number of subjects: 510
Study 37550831 — intervention group
Group type: EXPERIMENTAL
Intervention: Caregiver contribution to self-care management
Number of subjects: 510
Study 37550831 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall model
Number of subjects: 510
Study 37550942 — intervention group
Group type: EXPERIMENTAL
Intervention: mRNA vaccination
Number of subjects: 288
Study 37550942 — intervention group
Group type: EXPERIMENTAL
Intervention: non-mRNA vaccination
Number of subjects: 288
Study 37550942 — intervention group
Group type: EXPERIMENTAL
Intervention: serologic evidence of viral exposure
Number of subjects: 288
Study 37550942 — intervention group
Group type: EXPERIMENTAL
Intervention: ozanimod treatment
Number of subjects: 288
Study 37550958 — intervention group
Group type: EXPERIMENTAL
Intervention: PrecivityAD blood test (mass spectrometry test measuring amyloid beta and ApoE blood biomarkers)
Number of subjects: 366
Study 37550958 — intervention group
Group type: EXPERIMENTAL
Intervention: PrecivityAD blood test
Number of subjects: 366
Study 37551153 — intervention group
Group type: EXPERIMENTAL
Intervention: Intra-operative mean α power
Number of subjects: 220
Study 37551153 — intervention group
Group type: EXPERIMENTAL
Intervention: Intra-operative maximum α power
Number of subjects: 220
Study 37551153 — intervention group
Group type: EXPERIMENTAL
Intervention: Pre-operative cognitive z scores
Number of subjects: 220
Study 37551153 — intervention group
Group type: EXPERIMENTAL
Intervention: Age
Number of subjects: 220
Study 37551324 — intervention group
Group type: EXPERIMENTAL
Intervention: Active surveillance (weekly)
Number of subjects: 500
Study 37551324 — intervention group
Group type: EXPERIMENTAL
Intervention: Immunoglobulin G positivity
Number of subjects: 500
Study 37551412 — intervention group
Group type: EXPERIMENTAL
Intervention: 150 min/wk of moderate-intensity aerobic, resistance, or combination exercise
Number of subjects: 0
Study 37551412 — intervention group
Group type: COMPARATOR
Intervention: Non-exercising control
Number of subjects: 0
Study 37551512 — intervention group
Group type: EXPERIMENTAL
Intervention: Fortified human milk diet (intervention group)
Number of subjects: 150
Study 37551512 — intervention group
Group type: COMPARATOR
Intervention: Standard unfortified diet (control group)
Number of subjects: 150
Study 37551532 — intervention group
Group type: EXPERIMENTAL
Intervention: Drug-Eluting Balloon (DEB) angioplasty (SEQUENT PLEASE)
Number of subjects: 290
Study 37551532 — intervention group
Group type: COMPARATOR
Intervention: Drug-Eluting Stent (DES) (Promus Premier and Promus Elite)
Number of subjects: 290
Study 37551542 — intervention group
Group type: EXPERIMENTAL
Intervention: AID (MiniMed™ 780G)
Number of subjects: 75
Study 37551542 — intervention group
Group type: COMPARATOR
Intervention: MDI+isCGM (Control)
Number of subjects: 75
Study 37551550 — intervention group
Group type: EXPERIMENTAL
Intervention: Labisia pumila standardized extract (SKF7®) 750 mg
Number of subjects: 133
Study 37551609 — intervention group
Group type: EXPERIMENTAL
Intervention: Cariprazine 1.5 mg/d
Number of subjects: 0
Study 37551609 — intervention group
Group type: EXPERIMENTAL
Intervention: Cariprazine 3 mg/d
Number of subjects: 0
Study 37551609 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 37551762 — intervention group
Group type: EXPERIMENTAL
Intervention: Initial weight change (WC) during the initial 2, 4, and 8 weeks
Number of subjects: 452
Study 37551762 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-weighing and adherence to the expected WC trajectory
Number of subjects: 452
Study 37551841 — intervention group
Group type: COMPARATOR
Intervention: Fibrin-based haemostatic agents (FBHAs)
Number of subjects: 2945
Study 37552083 — intervention group
Group type: EXPERIMENTAL
Intervention: Local clinical site diagnoses
Number of subjects: 918
Study 37552083 — intervention group
Group type: EXPERIMENTAL
Intervention: Central, adjudicated review diagnoses
Number of subjects: 918
Study 37552083 — intervention group
Group type: EXPERIMENTAL
Intervention: Therapies reported
Number of subjects: 918
Study 37552083 — intervention group
Group type: COMPARATOR
Intervention: True discordance in diagnosis
Number of subjects: 918
Study 37552083 — intervention group
Group type: COMPARATOR
Intervention: Inappropriate therapy
Number of subjects: 918
Study 37552281 — intervention group
Group type: EXPERIMENTAL
Intervention: Osia 2 System
Number of subjects: 20
Study 37552303 — intervention group
Group type: EXPERIMENTAL
Intervention: Atorvastatin 40 mg/d (n=150)
Number of subjects: 300
Study 37552303 — intervention group
Group type: COMPARATOR
Intervention: Placebo (n=150)
Number of subjects: 300
Study 37552330 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin K4 (1 mg) for 24 weeks
Number of subjects: 90
Study 37552330 — intervention group
Group type: COMPARATOR
Intervention: Placebo for 24 weeks
Number of subjects: 90
Study 37552367 — intervention group
Group type: EXPERIMENTAL
Intervention: SGM-101 (carcinoembryonic antigen specific fluorescent tracer)
Number of subjects: 13
Study 37552407 — intervention group
Group type: EXPERIMENTAL
Intervention: Telmisartan (10-80 mg daily)
Number of subjects: 107
Study 37552407 — intervention group
Group type: COMPARATOR
Intervention: Enalapril (5-40 mg daily)
Number of subjects: 107
Study 37552407 — intervention group
Group type: EXPERIMENTAL
Intervention: Telmisartan
Number of subjects: 107
Study 37552407 — intervention group
Group type: COMPARATOR
Intervention: Enalapril
Number of subjects: 107
Study 37552872 — intervention group
Group type: EXPERIMENTAL
Intervention: EVAD tool for evaluating and classifying the severity of adverse events
Number of subjects: 0
Study 37552988 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dimensional mass cytometry analysis of peripheral blood immune composition
Number of subjects: 0
Study 37552988 — intervention group
Group type: EXPERIMENTAL
Intervention: Supervised and unsupervised analysis methods to study cell-type proportions
Number of subjects: 0
Study 37553227 — intervention group
Group type: EXPERIMENTAL
Intervention: Hydroxychloroquine for 5 days
Number of subjects: 198
Study 37553227 — intervention group
Group type: COMPARATOR
Intervention: Placebo for 5 days
Number of subjects: 198
Study 37553227 — intervention group
Group type: EXPERIMENTAL
Intervention: Hydroxychloroquine and Placebo
Number of subjects: 198
Study 37553238 — intervention group
Group type: EXPERIMENTAL
Intervention: Control charts for monitoring surgical outcomes provided to intervention hospitals
Number of subjects: 155362
Study 37553297 — intervention group
Group type: EXPERIMENTAL
Intervention: Palbociclib (50 mg/m2) in combination with standard four-drug re-induction chemotherapy
Number of subjects: 12
Study 37553297 — intervention group
Group type: COMPARATOR
Intervention: Standard four-drug re-induction chemotherapy
Number of subjects: 12
Study 37553338 — intervention group
Group type: EXPERIMENTAL
Intervention: Ad5-nCoV
Number of subjects: 200
Study 37553338 — intervention group
Group type: COMPARATOR
Intervention: inactivated SARS-CoV-2 vaccine
Number of subjects: 200
Study 37553467 — intervention group
Group type: EXPERIMENTAL
Intervention: PLX-R18 (1 million cells/kg)
Number of subjects: 21
Study 37553467 — intervention group
Group type: EXPERIMENTAL
Intervention: PLX-R18 (2 million cells/kg)
Number of subjects: 21
Study 37553467 — intervention group
Group type: EXPERIMENTAL
Intervention: PLX-R18 (4 million cells/kg)
Number of subjects: 21
Study 37553467 — intervention group
Group type: EXPERIMENTAL
Intervention: PLX-R18
Number of subjects: 21
Study 37553488 — intervention group
Group type: EXPERIMENTAL
Intervention: MRI-guided focused ultrasound (MRgFUS) treatment
Number of subjects: 99
Study 37553560 — intervention group
Group type: EXPERIMENTAL
Intervention: Multi-component SDM implementation program
Number of subjects: 126
Study 37553560 — intervention group
Group type: EXPERIMENTAL
Intervention: Qualitative process evaluation
Number of subjects: 126
Study 37553560 — intervention group
Group type: EXPERIMENTAL
Intervention: Qualitative data analysis
Number of subjects: 126
Study 37553637 — intervention group
Group type: EXPERIMENTAL
Intervention: Wilderness program (8-day expedition including backpacking, sea kayaking, gorge climbing, camping, bush-craft skills, and mindfulness practices, followed by a 4-day basecamp after 3 months)
Number of subjects: 59
Study 37553637 — intervention group
Group type: COMPARATOR
Intervention: Holiday program (8-day holiday program at a Spa-hotel followed by a 4-day holiday program at the same hotel after 3 months)
Number of subjects: 59
Study 37553688 — intervention group
Group type: COMPARATOR
Intervention: Traditional symptom severity decision-making algorithm
Number of subjects: 1000
Study 37553688 — intervention group
Group type: EXPERIMENTAL
Intervention: Novel multivariate decision-making algorithm
Number of subjects: 1000
Study 37553699 — intervention group
Group type: EXPERIMENTAL
Intervention: Ad libitum clear liquids up to 2 hours prior to procedure
Number of subjects: 181
Study 37553699 — intervention group
Group type: COMPARATOR
Intervention: Nil per os (NPO) after midnight (control group)
Number of subjects: 181
Study 37553840 — intervention group
Group type: EXPERIMENTAL
Intervention: Community Support Intervention (CSI)
Number of subjects: 33
Study 37553840 — intervention group
Group type: COMPARATOR
Intervention: Education group
Number of subjects: 33
Study 37553873 — intervention group
Group type: EXPERIMENTAL
Intervention: Bosutinib 500 mg QD
Number of subjects: 573
Study 37553873 — intervention group
Group type: EXPERIMENTAL
Intervention: Bosutinib 400 mg QD
Number of subjects: 573
Study 37553873 — intervention group
Group type: COMPARATOR
Intervention: Imatinib
Number of subjects: 573
Study 37553874 — intervention group
Group type: EXPERIMENTAL
Intervention: Berberine (BBR) hydrochloride
Number of subjects: 0
Study 37554074 — intervention group
Group type: EXPERIMENTAL
Intervention: Household members screened for depressive disorder using PHQ-9
Number of subjects: 0
Study 37554074 — intervention group
Group type: EXPERIMENTAL
Intervention: Household members with elevated depression symptom severity
Number of subjects: 0
Study 37554078 — intervention group
Group type: COMPARATOR
Intervention: Insulin-controlled euglycemia (control)
Number of subjects: 9
Study 37554078 — intervention group
Group type: EXPERIMENTAL
Intervention: Total insulin withdrawal for 14 hours
Number of subjects: 9
Study 37554123 — intervention group
Group type: EXPERIMENTAL
Intervention: Lenalidomide maintenance in TE patients
Number of subjects: 4358
Study 37554123 — intervention group
Group type: EXPERIMENTAL
Intervention: Lenalidomide maintenance in TNE patients
Number of subjects: 4358
Study 37554123 — intervention group
Group type: EXPERIMENTAL
Intervention: Double exposure to lenalidomide in TNE patients
Number of subjects: 4358
Study 37554125 — intervention group
Group type: EXPERIMENTAL
Intervention: Sintilimab (200 mg, day 1) plus bevacizumab (7.5 mg/kg, day 1), oxaliplatin (135 mg/m2, day 1), and capecitabine as first-line therapy
Number of subjects: 25
Study 37554125 — intervention group
Group type: EXPERIMENTAL
Intervention: Sintilimab plus bevacizumab, oxaliplatin and capecitabine
Number of subjects: 25
Study 37554125 — intervention group
Group type: EXPERIMENTAL
Intervention: Exploratory biomarker assessment
Number of subjects: 25
Study 37554174 — intervention group
Group type: EXPERIMENTAL
Intervention: Cell-based assay (CBA)
Number of subjects: 2272
Study 37554174 — intervention group
Group type: EXPERIMENTAL
Intervention: Radioimmunoprecipitation assay (RIPA)
Number of subjects: 2272
Study 37554174 — intervention group
Group type: EXPERIMENTAL
Intervention: Enzyme-linked immunosorbent assay (ELISA)
Number of subjects: 2272
Study 37554174 — intervention group
Group type: COMPARATOR
Intervention: CBA
Number of subjects: 2272
Study 37554284 — intervention group
Group type: EXPERIMENTAL
Intervention: Focused ultrasound
Number of subjects: 0
Study 37554394 — intervention group
Group type: EXPERIMENTAL
Intervention: taVNS (transcutaneous auricular vagus nerve stimulation)
Number of subjects: 30
Study 37554394 — intervention group
Group type: COMPARATOR
Intervention: Sham control
Number of subjects: 30
Study 37554510 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous reinduction of Ustekinumab (UST) followed by subcutaneous q8w or q4w
Number of subjects: 128
Study 37554510 — intervention group
Group type: COMPARATOR
Intervention: Shortening intervals of Ustekinumab (UST) q8w or q4w
Number of subjects: 128
Study 37555165 — intervention group
Group type: EXPERIMENTAL
Intervention: Endovascular baroreflex amplification (EVBA) by implantation of the MobiusHD
Number of subjects: 13
Study 37555197 — intervention group
Group type: COMPARATOR
Intervention: Heart attack education program delivered by trained HM Coordinators, supported by media and a geo-targeted social media campaign.
Number of subjects: 8
Study 37555284 — intervention group
Group type: EXPERIMENTAL
Intervention: Entinostat 2 mg orally weekly in combination with standard dose carboplatin, etoposide, and atezolizumab
Number of subjects: 3
Study 37555284 — intervention group
Group type: EXPERIMENTAL
Intervention: Entinostat, atezolizumab, carboplatin, and etoposide
Number of subjects: 3
Study 37555345 — intervention group
Group type: EXPERIMENTAL
Intervention: Percutaneous coronary intervention (PCI) plus optimal medical and device therapy (OMT)
Number of subjects: 700
Study 37555345 — intervention group
Group type: COMPARATOR
Intervention: Optimal medical and device therapy (OMT) alone
Number of subjects: 700
Study 37555595 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dose ato-oxy (0.5 mg/kg atomoxetine and 5 mg oxybutynin)
Number of subjects: 15
Study 37555595 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose ato-oxy (1.2 mg/kg atomoxetine and 5 mg oxybutynin)
Number of subjects: 15
Study 37555595 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 15
Study 37555595 — intervention group
Group type: EXPERIMENTAL
Intervention: Health-related quality of life (OSA-18)
Number of subjects: 15
Study 37555595 — intervention group
Group type: EXPERIMENTAL
Intervention: Changes in sleep architecture
Number of subjects: 15
Study 37555738 — intervention group
Group type: EXPERIMENTAL
Intervention: Carboxymethylcellulose artificial tears
Number of subjects: 80
Study 37555738 — intervention group
Group type: COMPARATOR
Intervention: Polyethylene glycol artificial tears
Number of subjects: 80
Study 37555886 — intervention group
Group type: EXPERIMENTAL
Intervention: Absolute Change (AC)
Number of subjects: 0
Study 37555886 — intervention group
Group type: EXPERIMENTAL
Intervention: Relative Change (RC)
Number of subjects: 0
Study 37555886 — intervention group
Group type: EXPERIMENTAL
Intervention: Proposed Responder Endpoint
Number of subjects: 0
Study 37555886 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher AC and RC thresholds
Number of subjects: 0
Study 37555901 — intervention group
Group type: EXPERIMENTAL
Intervention: GRPR-targeted PET using mPROMISE criteria
Number of subjects: 0
Study 37555901 — intervention group
Group type: EXPERIMENTAL
Intervention: mPROMISE criteria
Number of subjects: 0
Study 37555904 — intervention group
Group type: EXPERIMENTAL
Intervention: PD-1/L1 blockade
Number of subjects: 0
Study 37556023 — intervention group
Group type: EXPERIMENTAL
Intervention: Lurbinectedin 3.2 mg/m²
Number of subjects: 0
Study 37556078 — intervention group
Group type: EXPERIMENTAL
Intervention: RYHJ-GA (modified RYHJ with gastric access loop)
Number of subjects: 52
Study 37556078 — intervention group
Group type: COMPARATOR
Intervention: RYHJ-C (conventional RYHJ)
Number of subjects: 52
Study 37556123 — intervention group
Group type: EXPERIMENTAL
Intervention: Immediate coronary angiography
Number of subjects: 554
Study 37556123 — intervention group
Group type: COMPARATOR
Intervention: Delayed or selective angiography
Number of subjects: 554
Study 37556146 — intervention group
Group type: EXPERIMENTAL
Intervention: Baricitinib, 4 mg
Number of subjects: 1200
Study 37556146 — intervention group
Group type: COMPARATOR
Intervention: Baricitinib, 2 mg
Number of subjects: 1200
Study 37556150 — intervention group
Group type: EXPERIMENTAL
Intervention: 12-week app-based exercise intervention (four 20-minute sessions per week using body weight interval training, yoga, barre, and running apps)
Number of subjects: 288
Study 37556150 — intervention group
Group type: EXPERIMENTAL
Intervention: 12-week app-based exercise intervention
Number of subjects: 288
Study 37556150 — intervention group
Group type: COMPARATOR
Intervention: Wait list control
Number of subjects: 288
Study 37556188 — intervention group
Group type: EXPERIMENTAL
Intervention: Strengths-based prevention education intervention for Black girls
Number of subjects: 200
Study 37556188 — intervention group
Group type: EXPERIMENTAL
Intervention: Focus group methodology and surveys
Number of subjects: 200
Study 37556188 — intervention group
Group type: EXPERIMENTAL
Intervention: Pretest of the intervention with the youth advisory board
Number of subjects: 200
Study 37556515 — intervention group
Group type: EXPERIMENTAL
Intervention: Tildrakizumab 100 mg subcutaneously at week 0, week 4, and every 12 weeks thereafter
Number of subjects: 55
Study 37556515 — intervention group
Group type: EXPERIMENTAL
Intervention: Tildrakizumab 100 mg subcutaneously
Number of subjects: 55
Study 37556734 — intervention group
Group type: EXPERIMENTAL
Intervention: ETP phenotype
Number of subjects: 1256
Study 37556734 — intervention group
Group type: EXPERIMENTAL
Intervention: near-ETP phenotype
Number of subjects: 1256
Study 37556734 — intervention group
Group type: EXPERIMENTAL
Intervention: non-ETP phenotype
Number of subjects: 1256
Study 37556734 — intervention group
Group type: EXPERIMENTAL
Intervention: day-29 MRD ≥1% with end-consolidation MRD ≥0.01%
Number of subjects: 1256
Study 37556734 — intervention group
Group type: COMPARATOR
Intervention: day-29 MRD <0.01% vs 0.01% to 0.1%
Number of subjects: 1256
Study 37556775 — intervention group
Group type: EXPERIMENTAL
Intervention: Palbociclib
Number of subjects: 5698
Study 37556775 — intervention group
Group type: EXPERIMENTAL
Intervention: Palbociclib + Endocrine Therapy (ET)
Number of subjects: 5698
Study 37556856 — intervention group
Group type: EXPERIMENTAL
Intervention: Plyometric high-intensity interval training (PLYO), 8 weeks, twice weekly
Number of subjects: 0
Study 37556856 — intervention group
Group type: COMPARATOR
Intervention: Cycle-oriented high-intensity interval training (CYC), 8 weeks, twice weekly
Number of subjects: 0
Study 37556859 — intervention group
Group type: EXPERIMENTAL
Intervention: Loaded exercise
Number of subjects: 0
Study 37556859 — intervention group
Group type: EXPERIMENTAL
Intervention: Unloaded exercise
Number of subjects: 0
Study 37556859 — intervention group
Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 0
Study 37556913 — intervention group
Group type: EXPERIMENTAL
Intervention: BI 894999 (Schedule A: 0.2, 0.5, 1.0, 1.5, 2.0, and 5.0 mg, Days 1-21/21-d cycle)
Number of subjects: 77